A randomized, double-blind, placebo-controlled, phase II dose-finding study of the short acting β(1)-blocker, landiolol hydrochloride, in patients with suspected ischemic cardiac disease

The purpose of this study was to compare the safety and efficacy of the short-acting β(1)-receptor blocker, landiolol hydrochloride (0.06 and 0.125-mg/kg), to placebo during coronary computed tomography angiography (CTA) in a phase 2 dose-finding study. A total of 183 patients suspected of having is...

Descripción completa

Detalles Bibliográficos
Autores principales: Jinzaki, Masahiro, Hirano, Masaharu, Hara, Kazuhiro, Suzuki, Takahiko, Yamashina, Akira, Ikari, Yuji, Iino, Misako, Yamaguchi, Takuhiro, Kuribayashi, Sachio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2013
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3722440/
https://www.ncbi.nlm.nih.gov/pubmed/23784548
http://dx.doi.org/10.1007/s10554-013-0253-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3722440/
https://www.ncbi.nlm.nih.gov/pubmed/23784548
http://dx.doi.org/10.1007/s10554-013-0253-3

Ejemplares similares